Exhibit 10.18

 

AMENDMENT NO. 3 TO

MARKETING AND DISTRIBUTION AGREEMENT

DATED MARCH 30, 2007 BETWEEN

VITAL IMAGES, INC. AND TOSHIBA MEDICAL SYSTEMS CORPORATION

 

THIS AMENDMENT NO. 3 (the “Amendment”) is made as of March, 2008 by and between
Vital Images, Inc., a Minnesota corporation having its principal place of
business at 5850 Opus Parkway, Suite 300, Minnetonka, Minnesota 55343 USA
(“Vital Images”)  and Toshiba Medical Systems Corporation having its place of
business at 1385, Shimoishigami, Otawara-Shi, Tochigi 324-8550, Japan
(“Toshiba”).

 

This Amendment modifies the Marketing and Distribution Agreement dated March 30,
2007 between the parties. Under this Amendment, the following items in the
Agreement are modified as set forth below:

 

1.             Exhibit E: The pricing for licenses of and maintenance for the #
Products set forth in Exhibit E to the Marketing and Distribution Agreement are
revised as set forth in Exhibit E to this Amendment. All other provisions of
Exhibit E attached to the Marketing and Distribution Agreement, and Amendments 1
and 2 thereof, remain unchanged.

 

2.             This Amendment shall take effect as of March, 2008.

 

3.             Except as amended hereby, the Agreement shall remain in full
force and effect in accordance with its original terms. The amended portions of
the Agreement shall be read, wherever reasonable to do so, to be consistent with
the portions not so amended; provided that the amended portions shall be deemed
to control and any conflict shall be resolved in favor of such amended portions.

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by
their duly authorized representatives below.

 

VITAL IMAGES, INC.

 

TOSHIBA MEDICAL SYSTEMS
CORPORATION

 

 

 

 

 

 

By

/s/ Susan A. Wood

 

By

 /s/Satoshi Kimura

 

 

 

 

 

 

 

 

 

 

 

 

Name

Susan A. Wood

 

Name

Satoshi Kimura

 

 

 

 

 

 

Title

Executive Vice President,

 

Title

X-ray System Division General Manager

 

 

Product Marketing and Development

 

 

 

--------------------------------------------------------------------------------

# Confidential Treatment has been requested, the portion indicated has been
redacted and the redacted portion has been separately filed with the Securities
and Exchange Commission.

 

--------------------------------------------------------------------------------

 

EXHIBIT E

PRODUCT PRICE LIST

 

Exhibit E of the Agreement is modified by changing the pricing for the Product
set forth below and
adding the following packages:

 

License

 

U.S. (current)

 

U.S. (new)

 

Non-U.S. 
(current)

 

Non-U.S. (new)

 

# *

 

$

#

 

$

#

 

$

#

 

$

#

 

 

--------------------------------------------------------------------------------

*when and if available

 

ADDITIONAL SOFTWARE PACKAGE PRICING

 

 

 

Pricing for New Customers

 

Package

 

U.S.A. 
(2008)

 

Non-U.S.A. 
(2008)

 

Angio XA Basic Package

 

$

#

 

$

#

 

·      Vitrea â

 

 

 

 

 

·      # *

 

 

 

 

 

Angio XA CT Package

 

$

#

 

$

#

 

·      Vitrea â

 

 

 

 

 

·      # *

 

 

 

 

 

·      CT Perfusion option

 

 

 

 

 

·      Peripheral Vessel Probe option

 

 

 

 

 

 

--------------------------------------------------------------------------------

*when and if available

 

 

 

Pricing for Existing Customers off 
Maintenance**

 

Package

 

U.S.A. 
(2008)

 

Non-U.S.A. 
(2008)

 

Angio XA Basic Package

 

$

#

 

$

#

 

·      Vitrea â

 

 

 

 

 

·      # *

 

 

 

 

 

Angio XA CT Package

 

$

#

 

$

#

 

·      Vitrea â

 

 

 

 

 

·      # *

 

 

 

 

 

·      CT Perfusion option

 

 

 

 

 

·      Peripheral Vessel Probe option

 

 

 

 

 

 

--------------------------------------------------------------------------------

*when and if available

 

**Existing Customers on Maintenance will receive the products when and if they
are made available

 

# Confidential Treatment has been requested, the portion indicated has been
redacted and the redacted portion has been separately filed with the Securities
and Exchange Commission.

 

--------------------------------------------------------------------------------